Immunoprecise Antibodies Ltd
IPA2.070USD
0.000
Close 12/19, 16:00（ET）Quotes delayed by 15 min
95.54MMarket Cap
LossP/E TTM
More Details of Immunoprecise Antibodies Ltd Company
ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. It has several subsidiaries in North America and Europe including entities, such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the IPA Family). Its Contract Research Organizations (CRO) services include B cell Select; Phage Display; DeepDisplay; Abthena Bispecifics; LucinaTech Humanization; Affinity Maturation; Immunization, hybridoma, sequencing; rPEx protein manufacturing, and Cell line development. The Company utilizes custom antigen modeling, target analysis using Natural Language Processing and the HYFTTM analysis to lay the groundwork for the subsequent experimental phases.
Immunoprecise Antibodies Ltd Info
Ticker SymbolIPA
Company nameImmunoprecise Antibodies Ltd
IPO dateJan 30, 1987
CEODr. Jennifer Lynne Bath, Ph.D.
Number of employees- -
Security typeOrdinary Share
Fiscal year-endJan 30
AddressIndustrious 823 Congress Ave Suite 300
CityAUSTIN
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code78701
Phone16048060626
Websitehttps://www.ipatherapeutics.com/
Ticker SymbolIPA
IPO dateJan 30, 1987
CEODr. Jennifer Lynne Bath, Ph.D.
Company Executives of Immunoprecise Antibodies Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. Jennifer Lynne Bath, Ph.D.
Dr. Jennifer Lynne Bath, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
498.12K
--
Dr. Kamil Isaev
Dr. Kamil Isaev
Independent Director
Independent Director
3.19K
--
Mr. Dirk Witters
Mr. Dirk Witters
Independent Director
Independent Director
1.95K
--
Ms. Kari Graber
Ms. Kari Graber
Vice President - Commercial Services
Vice President - Commercial Services
700.00
--
Mr. Jonathan I. (Jon) Lieber
Mr. Jonathan I. (Jon) Lieber
Director
Director
--
--
Mr. Joseph Scheffler
Mr. Joseph Scheffler
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Dr. Shuji Sato
Dr. Shuji Sato
Vice President - Innovative Solutions
Vice President - Innovative Solutions
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Jennifer Lynne Bath, Ph.D.
Dr. Jennifer Lynne Bath, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
498.12K
--
Dr. Kamil Isaev
Dr. Kamil Isaev
Independent Director
Independent Director
3.19K
--
Mr. Dirk Witters
Mr. Dirk Witters
Independent Director
Independent Director
1.95K
--
Ms. Kari Graber
Ms. Kari Graber
Vice President - Commercial Services
Vice President - Commercial Services
700.00
--
Mr. Jonathan I. (Jon) Lieber
Mr. Jonathan I. (Jon) Lieber
Director
Director
--
--
Mr. Joseph Scheffler
Mr. Joseph Scheffler
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2026Q1
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2021
FY2020
By BusinessUSD
Name
Revenue
Proportion
Project revenue
3.13M
98.89%
Cryo storage revenue
33.00K
1.04%
Product sales revenue
2.00K
0.06%
By RegionUSD
Name
Revenue
Proportion
United States of America
2.45M
77.48%
Europe
520.00K
16.45%
Canada
174.00K
5.50%
Australia
18.00K
0.57%
Other
0.00
0.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Project revenue
3.13M
98.89%
Cryo storage revenue
33.00K
1.04%
Product sales revenue
2.00K
0.06%
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Charmquark TWEE
7.83%
Ingalls & Snyder LLC (Asset Management)
5.78%
Susquehanna International Group, LLP
1.07%
Bath (Jennifer Lynne)
1.07%
Renaissance Technologies LLC
0.47%
Other
83.77%
Shareholders
Shareholders
Proportion
Charmquark TWEE
7.83%
Ingalls & Snyder LLC (Asset Management)
5.78%
Susquehanna International Group, LLP
1.07%
Bath (Jennifer Lynne)
1.07%
Renaissance Technologies LLC
0.47%
Other
83.77%
Shareholder Types
Shareholders
Proportion
Corporation
7.92%
Investment Advisor/Hedge Fund
6.38%
Investment Advisor
1.44%
Individual Investor
1.23%
Hedge Fund
0.74%
Research Firm
0.18%
Venture Capital
0.08%
Bank and Trust
0.05%
Family Office
0.04%
Other
81.94%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
41
3.90M
8.45%
-302.90K
2025Q2
46
8.16M
23.11%
+1.40M
2025Q1
45
6.32M
13.81%
+742.61K
2024Q4
45
4.34M
9.53%
-1.30M
2024Q3
46
5.39M
19.68%
+72.87K
2024Q2
48
5.12M
19.96%
-156.62K
2024Q1
50
5.14M
20.20%
-196.19K
2023Q4
58
5.33M
20.96%
+124.72K
2023Q3
50
4.91M
19.67%
-438.42K
2023Q2
53
5.01M
20.08%
-885.29K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Charmquark TWEE
3.66M
7.92%
--
--
Jul 25, 2025
Ingalls & Snyder LLC (Asset Management)
2.78M
6.02%
+21.24K
+0.77%
Jun 30, 2025
Susquehanna International Group, LLP
699.24K
1.51%
-3.76K
-0.53%
Jun 30, 2025
Bath (Jennifer Lynne)
498.12K
1.08%
--
--
Aug 27, 2025
Renaissance Technologies LLC
40.48K
0.09%
+11.08K
+37.69%
Jun 30, 2025
Two Sigma Investments, LP
90.86K
0.2%
+273.00
+0.30%
Jun 30, 2025
XTX Markets LLC
91.38K
0.2%
+72.90K
+394.36%
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Immunoprecise Antibodies Ltd?
The top five shareholders of Immunoprecise Antibodies Ltd are:
Charmquark TWEE holds 3.66M shares, accounting for 7.92% of the total shares.
Ingalls & Snyder LLC (Asset Management) holds 2.78M shares, accounting for 6.02% of the total shares.
Susquehanna International Group, LLP holds 699.24K shares, accounting for 1.51% of the total shares.
Bath (Jennifer Lynne) holds 498.12K shares, accounting for 1.08% of the total shares.
Renaissance Technologies LLC holds 40.48K shares, accounting for 0.09% of the total shares.
Charmquark TWEE holds 3.66M shares, accounting for 7.92% of the total shares.
Ingalls & Snyder LLC (Asset Management) holds 2.78M shares, accounting for 6.02% of the total shares.
Susquehanna International Group, LLP holds 699.24K shares, accounting for 1.51% of the total shares.
Bath (Jennifer Lynne) holds 498.12K shares, accounting for 1.08% of the total shares.
Renaissance Technologies LLC holds 40.48K shares, accounting for 0.09% of the total shares.
What are the top three shareholder types of Immunoprecise Antibodies Ltd?
The top three shareholder types of Immunoprecise Antibodies Ltd are:
Charmquark TWEE
Ingalls & Snyder LLC (Asset Management)
Susquehanna International Group, LLP
Charmquark TWEE
Ingalls & Snyder LLC (Asset Management)
Susquehanna International Group, LLP
How many institutions hold shares of Immunoprecise Antibodies Ltd (IPA)?
As of 2025Q3, 41 institutions hold shares of Immunoprecise Antibodies Ltd, with a combined market value of approximately 3.90M, accounting for 8.45% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -14.66%.
What is the biggest source of revenue for Immunoprecise Antibodies Ltd?
In FY2026Q1, the Project revenue business generated the highest revenue for Immunoprecise Antibodies Ltd, amounting to 3.13M and accounting for 98.89% of total revenue.
